Artificial Epidemics: How Medical Activism Has Inflated the Diagnosis of Prostate Cancer and Depression (Kindle Single)
Artificial Epidemics: How Medical Activism Has Inflated the Diagnosis of Prostate Cancer and Depression (Kindle Single)
by Stewart Justman
Dr. Patrick Walsh's Guide to Surviving Prostate Cancer, Second Edition
Dr. Patrick Walsh's Guide to Surviving Prostate Cancer, Second Edition
by Patrick C. Walsh Janet Farrar Worthington
Our Price: $11.55
Used from: $2.64

Dr. Patrick Walsh's Guide to Surviving Prostate Cancer
Dr. Patrick Walsh's Guide to Surviving Prostate Cancer
by Patrick C. Walsh Janet Farrar Worthington
Our Price: $12.78
Used from: $12.78

The Decision: Your prostate biopsy shows cancer. Now what?: Medical insight, personal stories, and humor by a urologist who has been where you are now.
The Decision: Your prostate biopsy shows cancer. Now what?: Medical insight, personal stories, and humor by a urologist who has been where you are now.
by John C. McHugh M.D.
Our Price: $13.24
Used from: $9.49

You Can Beat Prostate Cancer: And You Don't Need Surgery to Do It
You Can Beat Prostate Cancer: And You Don't Need Surgery to Do It
by Robert J. Marckini
Our Price: $20.00
Used from: $4.19



Prostate Cancer Forum Links


<< 1 2 3 >>




Prostate Cancer Forum News


Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer ... - Sacramento Bee


Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer ...
Sacramento Bee
"We believe ERG testing by IHC and ISH will play an important role in novel diagnostic, prognostic, and predictive tests for prostate cancer," says Mara G. Aspinall, President of Ventana Medical Systems, Inc. "This license gives us a unique position ...

and more »

Read more...


Oncomine contributes to integrative genomic analysis of lethal castration ... - Sacramento Bee


Oncomine contributes to integrative genomic analysis of lethal castration ...
Sacramento Bee
Integrated analysis of copy number and mutation data identified loss of CHD1, a chromatin-modifying enzyme, as a key genetic event in ETS-negative prostate cancer. With Oncomine, the team was able to rapidly validate this observation across 13 ...

and more »

Read more...